Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.

被引：0

作者：

Vogel, Arndt

Chan, Stephen Lam

Ren, Zhenggang

Bai, Yuxian

Gu, Shanzhi

Lin, Xiaoyan

Chen, Zhendong

Jia, Weidong

Jin, Yongdong

Guo, Yabing

Hu, Xiaohua

Sultanbaev, Alexander Valerievich

Pazgan-Simon, Monika

Pisetska, Margaryta

Nip, Tsz Keung

Zhang, Haisong

Du, Jinghua

Cheng, Ann-Lii

Kaseb, Ahmed Omar

Qin, Shukui

机构：

[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany

[2] Chinese Univ Hong Kong, Hong Kong, Peoples R China

[3] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Dept Hepat Oncol, Shanghai, Peoples R China

[4] Harbin Med Univ, Dept Gastroenterol, Canc Hosp, Harbin, Peoples R China

[5] Hunan Canc Hosp, Dept Intervent Radiol, Changsha, Peoples R China

[6] Fujian Med Univ, Dept Oncol, Union Hosp, Fuzhou, Peoples R China

[7] Anhui Med Univ, Dept Oncol, Affiliated Hosp 2, Hefei, Peoples R China

[8] Anhui Prov Hosp, Dept Gen Surg, Hefei, Peoples R China

[9] UESTC, Sichuan Canc Hosp & Inst, Dept Med Oncol, Affiliated Canc Hosp,Sch Med, Chengdu, Peoples R China

[10] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Liver Canc Ctr, Guangzhou, Peoples R China

[11] Guangxi Med Univ, Dept Med Oncol, Affiliated Hosp 1, Nanning, Peoples R China

[12] State Autonomous Budgetary Healthcare Inst, Republican Clin Oncol Dispensary, MoH Republ Bashkortostan, Ufa, Russia

[13] Wroclaw Med Univ, Dept Infect Dis & Hepatol, Wroclaw, Poland

[14] Cent Badan Klinicznych P Napora, Wroclaw, Poland

[15] Communal Non Profit Enterprise Reg Ctr Oncol, Dept Liver & Pancreas Gland Oncosurg, Kharkiv, Ukraine

[16] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Jiangsu, Peoples R China

[17] Natl Taiwan Univ Hosp, Taipei, Taiwan

[18] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX, Peoples R China

[19] Canc Ctr Nanjing, Jinling Hosp, Nanjing, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4110

引用

页数：1

共 50 条

[1] Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Qin, Shukui
Chan, Stephen L.
Gu, Shanzhi
Bai, Yuxian
Ren, Zhenggang
Lin, Xiaoyan
Chen, Zhendong
Jia, Weidong
Jin, Yongdong
Guo, Yabing
Hu, Xiaohua
Meng, Zhiqiang
Liang, Jun
Cheng, Ying
Xiong, Jianping
Ren, Hong
Yang, Fang
Li, Wei
Chen, Yajin
Zeng, Yong
Sultanbaev, Alexander
Pazgan-Simon, Monika
Pisetska, Margaryta
Melisi, Davide
Ponomarenko, Dmitriy
Osypchuk, Yurii
Sinielnikov, Ivan
Yang, Tsai-Sheng
Liang, Xiao
Chen, Chunxia
Wang, Linna
Cheng, Ann-Lii
Kaseb, Ahmed
Vogel, Arndt
LANCET, 2023, 402 (10408): : 1133 - 1146
[2] Analysis of antidrug antibodies (ADA) to camrelizumab in CARES-310: The pivotal phase III study of camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma (uHCC)
Kaseb, A. O.
Bugni, J.
Karkhanis, M.
Meng, X.
Wei, T.
Zhou, M.
Shen, K.
Yang, C.
Yu, M.
Jang, S. H.
Ryan, K.
Alexander, L.
ANNALS OF ONCOLOGY, 2024, 35 : S671 - S672
[3] Clinical outcomes of camrelizumab plus rivoceranib vs sorafenib (CARES-310) as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC) of non-viral and viral etiology.
Shroff, Rachna T.
Shi, Wei
Wu, Xiuzhi
Meng, Xianzhang
Maj, Melissa
Ryan, Kristin
Galloway, Chris
Alexander, Laura
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
[4] Patient-reported outcomes (PROs) <65 or ≥ 65 years old (yo) from CARES-310 camrelizumab plus rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC)
Chan, Stephen Lam
Kaseb, Ahmed Omar
Shi, Wei
Alexander, Laura
Meng, Xianzhang
Park, Cheolhee
Ryan, Kristin
Vogel, Arndt
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 456 - 456
[5] Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
Qin, S.
Chan, L. S.
Gu, S.
Bai, Y.
Ren, Z.
Lin, X.
Chen, Z.
Jia, W.
Jin, Y.
Guo, Y.
Sultanbaev, A. V.
Pazgan-Simon, M.
Pisetska, M.
Liang, X.
Chen, C.
Nie, Z.
Wang, L.
Cheng, A-L.
Kaseb, A.
Vogel, A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1401 - S1402
[6] Impact of baseline liver function on survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab plus rivoceranib vs sorafenib: A post hoc analysis of study CARES-310.
Vogel, Arndt
Cheng, Ann-Lii
Shi, Wei
Jang, Seong
Alexander, Laura
Meng, Xianzhang
Raphael, Natalia
Chan, Stephen Lam
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 509 - 509
[7] Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma
Zou, Huimin
Lai, Yunfeng
Chen, Xianwen
Ung, Carolina Oi Lam
Hu, Hao
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2025, 18
[8] Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China
Wei, Jingxuan
Xu, Kai
Lin, Yingtao
Liu, Qiang
Zhou, Chongchong
Zhang, Pei
Ma, Rui
Zhang, Mengdie
Zhang, Lingli
Li, Xin
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (05) : 1189 - 1199
[9] Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System
Wenwang Lang
Lian Deng
Bei Huang
Dongmei Zhong
Gaofeng Zhang
Meijun Lu
Ming Ouyang
Clinical Drug Investigation, 2024, 44 : 149 - 162
[10] Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis to assess the impact of treatment with camrelizumab plus rivoceranib (cam plus rivo) on quality of life vs sorafenib (sora) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study CARES-310
Moon, A.
Raphael, N.
Chan, S. L.
Kaseb, A. O.
Jang, S. H.
Meng, X.
Cheng, A-L.
Qin, S.
Vogel, A.
ANNALS OF ONCOLOGY, 2024, 35 : S663 - S663

← 1 2 3 4 5 →